



ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 19306

Title: Era of direct acting antivirals in chronic hepatitis C - Who will benefit?

Reviewer’s code: 01524125

Reviewer’s country: China

Science editor: Yue-Li Tian

Date sent for review: 2015-05-05 19:47

Date reviewed: 2015-05-06 15:39

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

In this review, Dr. Fung described the benefit of DAA to patients with chronic HCV infection, the review is valuable for clinicians. I have following comments to this report. Major comments: 1) the author had not detailed the history of INF-based therapy, in that era, the effect of IFN-based treatment is largely dependent on the viral genotypes. 2) The author had not detailed the side effects of INF-based treatment and DAA therapy, so, the reader could not understand what favorable side effects are. Minor comments 1) The abstract is too simple to know the questions you raised and the answer you given. 2) Citations are inefficiency and imprecise. 3) Abbreviations are not consistent, in abstract DAA is “direct antiviral agents (DAA)”, while, in paper body, DAA is “direct-acting antiviral (DAA) agents”. 4) You claimed that “An estimated 170 million people worldwide are chronically infected with the hepatitis C virus (HCV), affecting 2-3 percent of the world population, and constituting a major health burden globally.[1]”, be sure to figure out whether “170 million people are chronically infected with HCV” or they are HCV antibody positive, actually, the HCV infection rate is not that high as WHO estimated. Could you find the original literature for “An estimated 170 million people worldwide are chronically infected with the hepatitis C virus (HCV), affecting 2-3



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

percent of the world population, and constituting a major health burden globally”?



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 19306

Title: Era of direct acting antivirals in chronic hepatitis C - Who will benefit?

Reviewer's code: 00182548

Reviewer's country: Romania

Science editor: Yue-Li Tian

Date sent for review: 2015-05-05 19:47

Date reviewed: 2015-05-28 02:11

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The article is very interesting and useful for clinicians. It would be good to mention the disadvantages of prior therapies against hepatitis C virus and possible adverse effects of new combinations of direct acting antivirals. The author can also mention the challenges that may arise in the future regarding the new therapies, as the emergence of drug resistance or naturally occurring polymorphism in HCV sequences which can compromise HCV treatment response. DAA must have the same explanation in abstract and article.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 19306

Title: Era of direct acting antivirals in chronic hepatitis C - Who will benefit?

Reviewer's code: 00069693

Reviewer's country: Brazil

Science editor: Yue-Li Tian

Date sent for review: 2015-05-05 19:47

Date reviewed: 2015-05-28 07:16

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

General considerations: In the way it is written, this review appeared to me closer to an editorial, which may explain the lack of references in the text, but does not justify the fact that it is necessary to cite the source of the information provided. Thus, it becomes imperative to add references whenever necessary, which provides credibility to the review of the text information. Special considerations: Abstract: lacked the term "acting" in "directing antiviral (DAA)." Text: the subtitle "Patients with established cirrhosis", the 5th line, I suggest changing "compensation" for "decompensation". Summary: As the manuscript already has the abstract, I suggest the author place this subtitle as Conclusions.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 19306

Title: Era of direct acting antivirals in chronic hepatitis C - Who will benefit?

Reviewer's code: 02374599

Reviewer's country: China

Science editor: Yue-Li Tian

Date sent for review: 2015-05-05 19:47

Date reviewed: 2015-06-03 19:44

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

The author summarized the using of direct acting antivirals (DAA) drugs for the treatment of chronic hepatitis C (CHC) infection, especially the limitation of the availability and the high cost. This review provided a development strategy for the clinical treatment of CHC patients using DAA drugs. However, there are still some minor revisions as follows: 1) It is suggested to complement a table or figure to summarize the using of DAA drugs in different patients. 2) Paragraphs of text lack of references, please add them. 3) Some abbreviations are not consistent, such as DAA. The full name is "directing antiviral" in abstract, whereas "direct acting antivirals" in text, please revise.